[{"id":"a9929cf7-40a1-4942-a4c2-1a9b6e8d511b","acronym":"NatHaLi-01","url":"https://clinicaltrials.gov/study/NCT05607420","created_at":"2022-11-07T13:56:26.754Z","updated_at":"2024-07-02T16:35:16.800Z","phase":"Phase 1/2","brief_title":"Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05607420 - NatHaLi-01","lead_sponsor":"Cellectis S.A.","biomarkers":" BCL2 • BCL6 • CD22","pipe":" | ","alterations":" CD20 positive • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • etivelcabtagene erigedleucel (UCART20x22)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2024-03-01"}]